Physician profile
Susan E Bostick
NPI 1659582369
$17,443.42
in general payments reported to CMS, 2019-2025
86 companies · $3,147 in 2025
The $3,147 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,842 · 2020: $1,214 · 2021: $2,409 · 2022: $3,023 · 2023: $2,833 · 2024: $2,976 · 2025: $3,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,756 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,755.89 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,835.24 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,381.77 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Astrazeneca Pharmaceuticals LP | $1,087.17 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Pfizer INC. | $1,041.37 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $941.24 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Incyte Corporation | $641.16 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $632.88 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Glaxosmithkline, LLC. | $594.67 | 2019-2025 | Ojjaara, Jemperli, Zejula |
| Seagen INC. | $532.04 | 2019-2025 | Padcev, Adcetris |
| Abbvie INC. | $516.05 | 2019-2025 | Venclexta |
| Amgen INC. | $488.06 | 2019-2023 | Kyprolis, Lumakras |
| Janssen Biotech, INC. | $484.99 | 2019-2025 | Darzalex, Talvey, Imbruvica |
| Celgene Corporation | $427.77 | 2020-2024 | Reblozyl, Pomalyst |
| Genzyme Corporation | $418.19 | 2019-2025 | |
| Genentech USA, INC. | $414.05 | 2019-2025 | Venclexta, Tecentriq, Polivy |
Show all 86 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $350.97 | 2019-2023 | Imbruvica, Epkinly |
| Eisai INC. | $326.35 | 2019-2025 | |
| Lilly USA, LLC | $316.21 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $303.05 | 2019-2025 | Libtayo, Lynozyfic |
| Bayer Healthcare Pharmaceuticals INC. | $294.93 | 2019-2025 | |
| Exelixis INC. | $282.45 | 2019-2025 | Cabometyx |
| Blueprint Medicines Corporation | $256.53 | 2020-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $191.44 | 2019-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Gilead Sciences, INC. | $188.76 | 2021-2025 | Trodelvy |
| Stemline Therapeutics INC. | $161.13 | 2020-2025 | Orserdu |
| Pharmaessentia USA Corporation | $147.92 | 2023-2025 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.16 | 2019-2025 | Gilotrif |
| Deciphera Pharmaceuticals INC. | $140.55 | 2021-2025 | Qinlock, Romvimza |
| Kite Pharma, INC. | $138.50 | 2021-2025 | Yescarta |
| Array Biopharma INC | $137.19 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Beigene USA, INC. | $130.77 | 2023-2024 | Brukinsa, Tevimbra |
| Karyopharm Therapeutics INC. | $128.89 | 2020-2025 | Xpovio |
| Myriad Genetic Laboratories, INC. | $121.25 | 2021-2024 | Bracanalysis Cdx |
| Astellas Pharma US INC | $118.67 | 2020-2025 | Xtandi |
| Alexion Pharmaceuticals, INC. | $109.74 | 2020-2025 | Ultomiris, Soliris |
| Beone Medicines USA, INC. | $102.98 | 2025 | Brukinsa, Tevimbra |
| Progenics Pharmaceuticals, INC. | $102.38 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $101.88 | 2022-2025 | |
| Emd Serono, INC. | $88.04 | 2019-2023 | Bavencio |
| Acrotech Biopharma INC. | $78.58 | 2021-2025 | Beleodaq |
| Tersera Therapeutics LLC | $77.06 | 2020-2025 | Zoladex, Quzyttir |
| Ipsen Biopharmaceuticals, INC | $69.69 | 2021-2023 | Onivyde, Somatuline Depot |
| Adc Therapeutics America, INC. | $67.59 | 2021-2022 | |
| Sobi, INC | $65.81 | 2022-2024 | |
| Puma Biotechnology, INC. | $64.33 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $63.72 | 2019-2024 | Tavalisse, Rezlidhia |
| Servier Pharmaceuticals LLC | $63.15 | 2022-2024 | |
| Dova Pharmaceuticals | $58.26 | 2019-2020 | |
| Coherus Oncology, INC. | $55.84 | 2024-2025 | Loqtorzi |
| Aveo Pharmaceuticals, INC. | $48.95 | 2022-2023 | Fotivda |
| Janssen Pharmaceuticals, INC | $48.88 | 2019-2024 | Xarelto |
| Agios Pharmaceuticals, INC. | $48.65 | 2022-2023 | Pyrukynd |
| Sun Pharmaceutical Industries INC. | $47.20 | 2022-2024 | |
| Genmab U.S., INC. | $47.01 | 2023-2025 | Epkinly |
| Myovant Sciences INC. | $46.37 | 2021-2022 | |
| Taiho Oncology, INC. | $43.89 | 2019-2023 | |
| Pharmacosmos Therapeutics INC. | $43.32 | 2024-2025 | Monoferric |
| Shield Therapeutics INC | $36.64 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $36.53 | 2022 | |
| Mirati Therapeutics, INC. | $35.70 | 2023 | Krazati |
| Adaptive Biotechnologies Corporation | $35.25 | 2023 | Clonoseq |
| Spectrum Pharmaceuticals INC. | $29.74 | 2019-2025 | Rolvedon |
| Immunocore Limited | $29.53 | 2025 | Kimmtrak |
| Siemens Medical Solutions USA, INC. | $25.42 | 2024 | Aria Radiation Therapy Management Software |
| Novocure INC. | $23.86 | 2025 | Optune Lua (Novottf-200t) |
| Eusa Pharma (US) LLC | $22.71 | 2019 | |
| Recordati_rare_diseases_inc. | $21.85 | 2025 | Enjaymo |
| Kyowa Kirin, INC. | $20.16 | 2025 | |
| Springworks Therapeutics, INC. | $19.53 | 2025 | Gomekli |
| Acceleron Pharma, INC. | $18.44 | 2021 | |
| Caris Mpi, INC. | $17.88 | 2025 | Mi Cancer Seek |
| Tg Therapeutics, INC. | $17.58 | 2021 | |
| Genentech, INC. | $16.98 | 2021 | |
| Amag Pharmaceuticals, INC. | $16.78 | 2022 | |
| Sumitomo Pharma America, INC. | $16.19 | 2024 | Orgovyx |
| Helsinn Therapeutics (U.S.), INC. | $14.96 | 2021 | |
| Geron Corporation | $14.61 | 2025 | Rytelo |
| Foundation Medicine, INC. | $14.08 | 2020 | |
| Tesaro, INC. | $13.89 | 2019 | |
| Global Blood Therapeutics, INC. | $13.61 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $13.15 | 2020 | |
| Secura Bio, INC. | $12.84 | 2020 | |
| Verastem, INC. | $12.32 | 2019 | |
| Immunomedics, INC. | $11.41 | 2020 | |
| Dendreon Pharmaceuticals LLC | $11.30 | 2019 | |
| Clovis Oncology, INC. | $10.79 | 2020 |
Drugs and devices associated with these payments
Enhertu $361Kisqali $324Keytruda $304Opdivo $298Imbruvica $296Lynparza $273Venclexta $265Imfinzi $260Scemblix $208Jakafi $199Ayvakit $182Brukinsa $181Xtandi $176Ojjaara $176Epkinly $174Adcetris $173Sarclisa $166Jemperli $165Padcev $159Verzenio $159Libtayo $157Pluvicto $157Besremi $148Orserdu $144Elrexfio $143Jaypirca $142Fabhalta $138Lenvima $134Calquence $127Braftovi $123Mektovi $123Cabometyx $122Injectafer $116Monjuvi $115Talzenna $105Orgovyx $104Darzalex $100Nubeqa $96.29Tecentriq $94.41Inlyta $92.45Lutathera $88.08Oxbryta $87.77Lorbrena $86.77Talvey $85.97Qinlock $84.46Ultomiris $82.12Reblozyl $79.31Xpovio $76.93Tukysa $68.86Piqray $68.40Krazati $66.76Stivarga $66.07Vitrakvi $66.07Xalkori $65.84Opdualag $65.20Tasigna $64.76Polivy $63.09Trodelvy $61.67Bosulif $61.30Zejula $61.02Comirnaty $60.01Yescarta $56.77Elahere $53.23Tevimbra $52.73Carvykti $52.44Retevmo $52.36Tecvayli $52.13Alunbrig $52.08Tibsovo $47.68Promacta $47.58Lynozyfic $46.99Gilotrif $46.52Fruzaqla $44.17Enjaymo $43.45Monoferric $43.32Pomalyst $42.49Ibrance $41.82Blenrep $40.63Doptelet $38.91Accrufer $36.64Besponsa $36.55Tivdak $36.49Pyrukynd $36.25Udenyca $36.25Pemazyre $35.89Paxlovid $35.56Pylarify $35.28Clonoseq $35.25Rybrevant $34.69Ziihera $34.39Somatuline Depot $33.10Onivyde $33.10Xarelto $32.71Romvimza $32.26Ninlaro $31.83Kimmtrak $29.53Zoladex $27.62Mekinist $27.57Zepzelca $26.82Bavencio $26.73
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Bostick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.